Clinical Trial Update: Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) [Phase 2]

View source ↗

Summary

Phase 2 trial in younger patients with intermediate-risk acute myeloid leukemia compares cytarabine + daunorubicin with and without venetoclax, and venetoclax +…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• CYTARABINE (CYTARABINE)
• Daunorubicin (daunorubicin)
• Venetoclax (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING